Switzerland-based Novartis has agreed to acquire IFM Tre from IFM Therapeutics, a United States biopharma company, in order to add certain immunomodulatory medicines to its range, it was reported yesterday.
The deal is valued at up to USD1.575bn. According to the terms of the deal, IFM Therapeutics will receive upfront payments of USD310m from Novartis and will be eligible to receive up to USD1.265bn in the form of milestone payments. The deal, which will be subject to customary closing conditions, is likely to be completed during the second quarter of 2019.
Through the acquisition, Novartis will obtain complete rights to IFM Tre's NLPR3 antagonist portfolio, made up of one clinical and two pre-clinical programs. The clinical stage program in the deal is IFM-2427, which is a systemic antagonist for a range of chronic inflammatory disorders such as atherosclerosis and nonalcoholic steatohepatitis. The two IFM Tre pre-clinical stage programs to be acquired by Novartis under the deal are a gut-directed molecule for the treatment of inflammatory bowel disease, and a central nervous system-penetrant molecule.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference